共 157 条
[1]
Wolf PA(1991)Atrial fibrillation as an independent risk factor for stroke: the framingham study Stroke 22 983-988
[2]
Abbott RD(2013)Atrial fibrillation, stroke risk, and warfarin therapy revisited Stroke 44 3103-3108
[3]
Kannel WB(2015)Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation J Am Heart Assoc 4 e001486-3335
[4]
Björck S(2009)Age disparities in stroke quality of care and delivery of health services Stroke 40 3328-2962
[5]
Palaszewski B(2016)2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS Eur Heart J 37 2893-314
[6]
Friberg L(2017)Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation Heart 103 307-2372
[7]
Bergfeldt L(2016)Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: temporal trends 2011–2015 in Denmark Sci Rep 6 31477-146
[8]
Haim M(2011)Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation Circulation 123 2363-1872
[9]
Hoshen M(2014)Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism Circulation 130 138-681
[10]
Reges O(2014)Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the Aristotle trial Eur Heart J 35 1864-1236